CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

144 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
Clear
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
AERBB2L755APredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTrastuzumab DeruxtecanGoto et al., 2023
AERBB2G778_P780dupPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTrastuzumab DeruxtecanGoto et al., 2023
DERBB2L755_T759delPredictiveSupportsSensitivity/ResponseBreast CancerNeratinibBose et al., 2013
DERBB2AmplificationPredictiveSupportsSensitivity/ResponseUterine Corpus Endometrial CarcinomaAfatinibSchwab et al., 2014
BERBB2AmplificationPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerLapatinib,Afatinib,TrastuzumabRimawi et al., 2015
DERBB2AmplificationPredictiveSupportsSensitivity/ResponsePancreatic AdenocarcinomaAfatinibHuguet et al., 2016
BERBB2AmplificationPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaTrastuzumabGatzemeier et al., 2004
BERBB2AmplificationPredictiveDoes Not SupportSensitivity/ResponseEndometrial CancerTrastuzumabFleming et al., 2010
DERBB2AmplificationPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerA66Utermark et al., 2012
DERBB2AmplificationPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerPalbociclib,TrastuzumabFinn et al., 2009
DERBB2AmplificationPredictiveSupportsSensitivity/ResponseBreast CancerMTOR Kinase Inhibitor PP242Weigelt et al., 2011
BERBB2AmplificationPredictiveSupportsResistanceColorectal CancerPanitumumab,CetuximabMartin et al., 2013
CERBB2AmplificationPredictiveSupportsSensitivity/ResponseScrotum Paget's DiseaseTrastuzumabBarth et al., 2015
BERBB2Y772_A775DUPPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaDacomitinibKris et al., 2015
DERBB2V773APredictiveSupportsSensitivity/ResponseCancerLapatinibKancha et al., 2011
DERBB2N857SPredictiveSupportsSensitivity/ResponseCancerLapatinibKancha et al., 2011
DERBB2H878YPredictiveSupportsSensitivity/ResponseCancerLapatinibKancha et al., 2011
CERBB2OverexpressionPredictiveSupportsSensitivity/ResponseHead And Neck Squamous Cell CarcinomaLapatinibSeim et al., 2017
DERBB2L755SPredictiveSupportsResistanceCancerLapatinibKancha et al., 2011
DERBB2L755PPredictiveSupportsResistanceCancerLapatinibKancha et al., 2011
DERBB2T798MPredictiveSupportsResistanceCancerLapatinibKancha et al., 2011
BERBB2MutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaPertuzumab,TrastuzumabHainsworth et al., 2018
BERBB2AmplificationPredictiveSupportsSensitivity/ResponseBiliary Tract CancerPertuzumab,TrastuzumabHainsworth et al., 2018
BERBB2AmplificationPredictiveSupportsSensitivity/ResponseSalivary Gland CarcinomaPertuzumab,TrastuzumabHainsworth et al., 2018
BERBB2AmplificationPredictiveSupportsSensitivity/ResponsePancreatic CancerPertuzumab,TrastuzumabHainsworth et al., 2018
BERBB2AmplificationPredictiveDoes Not SupportSensitivity/ResponseUterine CancerTrastuzumab,PertuzumabHainsworth et al., 2018
CERBB2OverexpressionPredictiveSupportsSensitivity/ResponseSalivary Gland CancerTrastuzumab,PaclitaxelFirwana et al., 2012
DERBB2V777LPredictiveSupportsSensitivity/ResponseCancerLapatinibKancha et al., 2011
CERBB2S310FPredictiveSupportsSensitivity/ResponseBreast CancerAfatinibBedard et al., 2022
AERBB2L755MPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTrastuzumab DeruxtecanGoto et al., 2023
AERBB2L755PPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTrastuzumab DeruxtecanGoto et al., 2023
AERBB2A775_G776insTVMAPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTrastuzumab DeruxtecanGoto et al., 2023
AERBB2A775_G776insVPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTrastuzumab DeruxtecanGoto et al., 2023
AERBB2A775_G776insVVMAPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTrastuzumab DeruxtecanGoto et al., 2023
AERBB2G776_V777delinsVCDPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTrastuzumab DeruxtecanGoto et al., 2023
CERBB2G776delinsCVPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTrastuzumab DeruxtecanGoto et al., 2023
AERBB2G776delinsLCPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTrastuzumab DeruxtecanGoto et al., 2023
AERBB2G778_S779insLPSPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTrastuzumab DeruxtecanGoto et al., 2023
BERBB2AmplificationPredictiveDoes Not SupportResistanceColorectal CancerCetuximab,Capecitabine,OxaliplatinSclafani et al., 2013
CERBB2AmplificationPredictiveSupportsResistanceLung AdenocarcinomaGefitinib,ErlotinibYu et al., 2013
DERBB2T862APredictiveSupportsSensitivity/ResponseCancerLapatinibKancha et al., 2011
BERBB2AmplificationPredictiveSupportsSensitivity/ResponseChildhood EpendymomaLapatinibFouladi et al., 2010
CERBB2D769YPredictiveSupportsSensitivity/ResponsePeritoneal CarcinomaAfatinibBedard et al., 2022
CERBB2V777LPredictiveSupportsSensitivity/ResponseBreast CancerAfatinibBedard et al., 2022
Page 3 of 3
Previous